HC Wainwright & Co. Maintains Buy Rating for Entrada Therapeutics: Here's What You Need To Know

HC Wainwright & Co. has decided to maintain its Buy rating of Entrada Therapeutics TRDA and lower its price target from $25.00 to $20.00.

Shares of Entrada Therapeutics are trading up 0.17% over the last 24 hours, at $11.51 per share.

A move to $20.00 would account for a 73.76% increase from the current share price.

About Entrada Therapeutics

Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.